Latham & Watkins·FDA / LIFE SCIENCES REGULATORY

CMS Advances Drug Pricing Policies Under IRA and MFN Models

All 50 states have opted into the MFN-related "Generous" payment model, and CMS will begin testing a new 340B data repository for Part D inflation rebates on October 1.

drug-pricingcmsinflation-reduction-act340b-programmfnhealthcare-regulatory

Read the original firm alert → Wednesday, September 23, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.